Summary
In The Netherlands, the rate of consumption of medicine is low compared with that in other member states of the European Community. Nevertheless, expenditure on medicines is high in this country, because of a high price level. In the past decade, the cost of medicines has been growing more rapidly than the total expenditure on healthcare in The Netherlands. This prompted The Netherlands government to take action against the rise in the cost of medicines. Some policies were directed at the volume of consumption, but most focused on price. All had in common that they failed to produce lasting cost containment or did not stand up in court or to political debate. As a result, the measures proposed and implemented by the government have become increasingly harsh, departing from the Dutch tradition of harmonious policy-making carried out jointly by government and societal groups. The latest step has been the introduction (as of July 1,1993) of a new version of a price reference system, which discourages the prescription of innovative but expensive drugs. It is too early to tell whether this policy will have a more enduring effect on cost than the previous measures.
Similar content being viewed by others
References
Burstall ML. Europe after 1992: implications for pharmaceuticals. Health Aff 1991; 10 (3): 157–71
Department of Welfare, Health and Culture. Zorg in Nederland 1994. Rijswijk, 1993
IWI-Studien, Band II. Die osterreichische Pharmawirtschaft: Ihre Rolle im Gesundheitswesen und Stellung im internationale Vergleich, 1991
Nederlandse Vereniging van de Farmaceutische Industrie van Zelfzorggeneesmiddelen. Zelfzorggeneesmiddelen in Nederland. Neprofarm, Utrecht, 1993
Nederlandse Industrie van de Farmaceutische Industrie van Zelfzorggeneesmiddelen. 1992-gegevens over zelfzorggeneesmiddelen. Neprofarm, Utrecht, 1993
Burstall ML. 1992 and the pharmaceutical industry. IEA Health and Welfare Unit, London, 1990
Ziekenfondsraad/Geneesmiddelen Informatie Project. GIPeilingen 1989–1990. Amstelveen, 1992
Algemene Rekenkamer. Kostenbeheersing geneesmiddelen. Den Haag, Sdu Uitgeverij Plantijnstraat, 1992
Stuurgroep Toekomstscenario’s Gezondheidszorg. De toekomstvan het geneesmiddel in de gezondheidszorg. Bohn Stafleu Van Loghum, Houten/Zaventem, 1993
Ferrari MD, Haan J, Bax WA, et al. Onterechte gelijkschakeling van sumatriptan met ergotamine en dihydroergotamine in het Geneesmiddelen Vergoedings Systeem. Ned Tijdschr Geneeskd 1993; 137: 846–55
State Secretary of Welfare, Health, and Culture. Kostenbeheersing geneesmiddelen, White Paper presented to Parliament, April 22, 1993
State Secretary of Welfare, Health and Culture. Ontwerp-Regeling farmaceutische hulp 1993, White Paper presented to Parliament, May 11, 1993
Stenfert Kroese H. We moeten de tering naar de nering zetten (interview with CM. de Vos, Department of Welfare, Health, and Culture). De Huisarts in Nederland, May 8-213, 1993
Overleg tussen organisaties binnen de farmaceutische bedrijfskolom, Letter to the State Secretary of Welfare, Health, and Culture. Nefarma, Utrecht, May 19, 1993
Van Winzum C. Geneesmiddeleninnovatie, Europa en politiek: een wensbeeld. Mediator 1993; 4 (2): 8–10
Timmerman H. Huidige ontwikkelingen funest voor industrie en gezondheidszorg (interview). Innovator 1993; 1 (1): 20–2
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rigter, H. Recent Public Policies in The Netherlands to Control Pharmaceutical Pricing and Reimbursement. Pharmacoeconomics 6 (Suppl 1), 15–21 (1994). https://doi.org/10.2165/00019053-199400061-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199400061-00007